Lehigh Valley Hospital- Muhlenberg
Welcome,         Profile    Billing    Logout  
 5 Trials 
10 Trials

   

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Wright, David W
ENDOLOW, NCT04167527: Endovascular Therapy for Low NIHSS Ischemic Strokes

Recruiting
2/3
200
Europe, Canada, US
Immediate mechanical thrombectomy(iMT) using EmboTrap Revascularization Device, EmboTrap III, Initial medical management (iMM)
Emory University, University of Calgary, University of Cincinnati, Heidelberg University, Children's Hospital Medical Center, Cincinnati
Cerebral Ischemia
12/24
12/24
COMPANION-003, NCT05513742: A Study of CTX-009 in Adult Patients With Metastatic Colorectal Cancer

Active, not recruiting
2
84
US
CTX-009
Compass Therapeutics
Metastatic Colorectal Cancer, Colon Cancer, Rectal Cancer
06/24
12/24
TAPUR, NCT02693535: Testing the Use of Food and Drug Administration (FDA) Approved Drugs That Target a Specific Abnormality in a Tumor Gene in People With Advanced Stage Cancer

Recruiting
2
3791
US
Palbociclib, Ibrance, Sunitinib, Sutent, Temsirolimus, Torisel, Trastuzumab and Pertuzumab, Herceptin and Perjeta, Vemurafenib and Cobimetinib, Zelboraf and Cotellic, Regorafenib, Stivarga, Olaparib, Lynparza, Pembrolizumab, Keytruda, Nivolumab and Ipilimumab, Opdivo and Yervoy, Abemaciclib, Verzenio, Talazoparib, Talzenna, Atezolizumab and PHESGO, Tecentriq and PHESGO, Atezolizumab and Talazoparib, Tecentriq and Talzenna, Entrectinib, Rozlytrek, Larotrectinib, Vitrakvi, Tucatinib plus Trastuzumab Subcutaneous (SC), Tukysa and Herceptin Hylecta, Futibatinib, Lytgobi
American Society of Clinical Oncology, AstraZeneca, Bayer, Bristol-Myers Squibb, Eli Lilly and Company, Genentech, Inc., Merck Sharp & Dohme LLC, Pfizer, Boehringer Ingelheim, Seagen Inc., Taiho Oncology, Inc.
Lymphoma, Non-Hodgkin, Multiple Myeloma, Advanced Solid Tumors
06/26
06/27
TEaM, NCT04576715: TBI Evaluation and Management

Recruiting
N/A
1000
US
TEaM Intervention, TEaM, Standard of Care
Emory University, Children's Healthcare of Atlanta
Mild Traumatic Brain Injury
01/25
01/25
PACT, NCT04100564: LITES Task Order 0005 Prehospital Airway Control Trial

Recruiting
N/A
2009
US
Supraglottic airway device, LMA, King, igel, Standard airway management
Jason Sperry, United States Department of Defense
Trauma Injury, Airway Control
03/25
03/26
Go-DCM, NCT03843255: Defining the Genetics, Biomarkers and Outcomes for Dilated Cardiomyopathy

Recruiting
N/A
2000
Europe
Part 1: DCM Cohort, Whole genome sequencing and biomarker analysis, Part 2: Heritable CV Diseases and Family Members, Biomarker analysis
Imperial College London, British Heart Foundation, Royal Brompton & Harefield NHS Foundation Trust
Dilated Cardiomyopathy, Cardiovascular Diseases
07/27
07/27
Khalil, Maged
EV-ECLIPSE, NCT05239624: Enfortumab Vedotin and Pembrolizumab in People With Bladder Cancer

Recruiting
2
23
US
Enfortumab vedotin, Pembrolizumab
Memorial Sloan Kettering Cancer Center, Astellas Pharma US, Inc., Seagen Inc., Merck Sharp & Dohme LLC
Urothelial Carcinoma
06/25
06/25
TAPUR, NCT02693535: Testing the Use of Food and Drug Administration (FDA) Approved Drugs That Target a Specific Abnormality in a Tumor Gene in People With Advanced Stage Cancer

Recruiting
2
3791
US
Palbociclib, Ibrance, Sunitinib, Sutent, Temsirolimus, Torisel, Trastuzumab and Pertuzumab, Herceptin and Perjeta, Vemurafenib and Cobimetinib, Zelboraf and Cotellic, Regorafenib, Stivarga, Olaparib, Lynparza, Pembrolizumab, Keytruda, Nivolumab and Ipilimumab, Opdivo and Yervoy, Abemaciclib, Verzenio, Talazoparib, Talzenna, Atezolizumab and PHESGO, Tecentriq and PHESGO, Atezolizumab and Talazoparib, Tecentriq and Talzenna, Entrectinib, Rozlytrek, Larotrectinib, Vitrakvi, Tucatinib plus Trastuzumab Subcutaneous (SC), Tukysa and Herceptin Hylecta, Futibatinib, Lytgobi
American Society of Clinical Oncology, AstraZeneca, Bayer, Bristol-Myers Squibb, Eli Lilly and Company, Genentech, Inc., Merck Sharp & Dohme LLC, Pfizer, Boehringer Ingelheim, Seagen Inc., Taiho Oncology, Inc.
Lymphoma, Non-Hodgkin, Multiple Myeloma, Advanced Solid Tumors
06/26
06/27
NCT04165772: Study of Induction PD-1 Blockade in Subjects With Locally Advanced Mismatch Repair Deficient Solid Tumors

Recruiting
2
200
US
TSR-042 or Dostarlimab, Dostarlimab, capecitabine or 5-FU, Intensity Modulated Radiation Therapy (IMRT)
Memorial Sloan Kettering Cancer Center, Tesaro, Inc.
Rectal Adenocarcinoma, Clinical Stage: Stage II (T3-4, N-), Stage III (Any T, N+), Solid Tumor, Solid Tumor, Adult
11/26
11/26
Mohindra, Amit
TAPUR, NCT02693535: Testing the Use of Food and Drug Administration (FDA) Approved Drugs That Target a Specific Abnormality in a Tumor Gene in People With Advanced Stage Cancer

Recruiting
2
3791
US
Palbociclib, Ibrance, Sunitinib, Sutent, Temsirolimus, Torisel, Trastuzumab and Pertuzumab, Herceptin and Perjeta, Vemurafenib and Cobimetinib, Zelboraf and Cotellic, Regorafenib, Stivarga, Olaparib, Lynparza, Pembrolizumab, Keytruda, Nivolumab and Ipilimumab, Opdivo and Yervoy, Abemaciclib, Verzenio, Talazoparib, Talzenna, Atezolizumab and PHESGO, Tecentriq and PHESGO, Atezolizumab and Talazoparib, Tecentriq and Talzenna, Entrectinib, Rozlytrek, Larotrectinib, Vitrakvi, Tucatinib plus Trastuzumab Subcutaneous (SC), Tukysa and Herceptin Hylecta, Futibatinib, Lytgobi
American Society of Clinical Oncology, AstraZeneca, Bayer, Bristol-Myers Squibb, Eli Lilly and Company, Genentech, Inc., Merck Sharp & Dohme LLC, Pfizer, Boehringer Ingelheim, Seagen Inc., Taiho Oncology, Inc.
Lymphoma, Non-Hodgkin, Multiple Myeloma, Advanced Solid Tumors
06/26
06/27

Download Options